Rocket Pharmaceuticals (RCKT) Total Current Liabilities (2014 - 2026)

Rocket Pharmaceuticals has reported Total Current Liabilities for 13 years, with the latest figure at $24.5 million in Q1 2026.

• Quarterly Total Current Liabilities fell 30.71% year-over-year to $24.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $24.5 million (down 30.71% YoY) and the FY2025 annual result came in at $30.2 million, down 25.75% from the prior year.
• Total Current Liabilities eased to $24.5 million in Q1 2026 per RCKT's latest filing, from $30.2 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $48.5 million in Q4 2023 and troughed at $22.6 million in Q1 2022.
• A 5-year average of $34.1 million and a median of $33.5 million in 2023 frame the typical range for Total Current Liabilities.
• The widest YoY moves for Total Current Liabilities: up 76.7% in 2022, down 44.26% in 2022.
• Over 5 years, Total Current Liabilities stood at $39.2 million in 2022, then gained by 23.84% to $48.5 million in 2023, then slipped by 16.12% to $40.7 million in 2024, then declined by 25.75% to $30.2 million in 2025, then fell by 19.0% to $24.5 million in 2026.
• According to Business Quant data, Total Current Liabilities over the past three periods registered $24.5 million, $30.2 million, and $31.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.